Advertisement
Emflaza (deflazacort) has been approved by the U.S. Food and Drug Administration to treat Duchenne muscular dystrophy in patients 5 years and older

FDA Approves Emflaza for Duchenne Muscular Dystrophy

0
Approved to treat Duchenne muscular dystrophy in patients 5 years and older
Daily low-dose aspirin may increase the live birth rate for women with high levels of inflammation who previously lost a pregnancy

Miscarriage Risk in Women With High hsCRP Down With Aspirin

0
Findings in women attempting conception with elevated hsCRP and prior pregnancy loss
The monophasic hyaluronic acid filler with lidocaine

Monophasic HA Filler + Lidocaine Corrects Nasolabial Folds

0
Monophasic hyaluronic acid filler, Dermalax implant plus, not inferior to biphasic HA Sub-Q
Concomitant use of valproic acid and meropenem is associated with a decrease in valproic acid plasma levels

Valproic Acid Plasma Levels Down With Concomitant Meropenem

0
Concomitant use of meropenem linked to decrease in VPA plasma level, regardless of MEPM dose
For patients with impaired glucose tolerance

Valsartan Cuts Microalbuminuria in Impaired Glucose Tolerance

0
No difference in ESRD or doubling of serum creatinine with valsartan versus placebo
Intravenous lidocaine seems safe for reducing pain among patients in the intensive care unit with varying degrees of organ dysfunction

Intravenous Lidocaine Offers Alternative for ICU Patients’ Pain

0
Findings in patients in intensive care unit with varying degrees of organ dysfunction
For patients with rheumatoid arthritis

Infection Risk Lower for Etanercept Vs Monoclonal Ab Rx

0
Findings from meta-analysis of patients with rheumatoid arthritis
For women undergoing cesarean section

Post-Cesarean Maternal Infection in 8.8 Percent of C-Sections

0
Odds of maternal infection up with black race, non-transverse uterine incision, surgery >49 minutes
In response to revised osteoporosis recommendations in 2008

Shift in Bisphosphonate Tx After 2008 Recommendations

0
From 2008 to 2012, drop in proportion of younger women, increase in women aged ≥65 years
For patients with type 2 diabetes

Novel Oral Glucose Lowering Drugs Cut Risks in T2DM

0
Reduced risk of all-cause mortality and CVD with dapagliflozin; lower risk of mortality with DPP-4i